After more than a year of exchanges and preparations, ACTL targeted anti-tumor cell immune technology finally settled in Hefei, Anhui Province, and patients in and around Anhui Province can receive this advanced anti-tumor treatment nearby.

Recently, the Hefei Tumor Hospital of the Chinese Academy of Sciences completed the first case of ACTL treatment in the province, and performed later observations.

"In February 2016, the second tumor ward of our hospital carried out ACTL multi-target targeted anti-tumor cell immune technology treatment for two tumor patients for the first time. After the treatment, the patients had no obvious discomfort. Now we will observe the patients in the later period.

One patient had duodenal cancer with multiple metastases throughout the body and had incomplete intestinal obstruction. There was no surgery, radiotherapy or chemotherapy. Traditional treatment can only provide symptomatic and supportive treatment, but the ACTL targeted anti-tumor cellular immune technology has low requirements on the physical fitness of patients. After consultation and consultation with experts in relevant departments of the hospital and solicitation of opinions from family members, it was decided to select the corresponding targeted treatment plan for the patient. The first cell extraction was performed on February 1, 2016, and the cultured immune cells were reinfused on February 16. Another patient was a patient with metastasis to the abdominal cavity after radiotherapy for middle and lower esophageal cancer, and the technique was also used to infuse the cultured immune cells.

According to Zhang Liwei, director of the second tumor ward, cellular immunotherapy is an emerging anti-tumor treatment method that makes up for the disadvantages of traditional surgery, radiotherapy, and chemotherapy. The ACTL targeted tumor cell immune technology promoted by our hospital has a wide range of indications. It can be applied to a variety of tumors and postoperative patients, patients with radiotherapy and chemotherapy, patients with chemotherapy resistance, and patients with metastatic or recurring advanced tumors.

In recent years, our hospital has actively carried out the clinical application of comprehensive tumor treatment. The successful implementation of ACTL targeted anti-tumor cellular immune technology has provided more treatment options for patients at various tumor stages and opened up new areas. "

ACTL technology transfects dendritic cells (DC cells) with genetically engineered vectors carrying tumor-associated antigens to activate cytotoxic T lymphocytes (CTL cells) in the human immune system so that they can effectively recognize and kill tumors. It is a targeted cellular immunotherapy technology, which can be widely used in the treatment of various malignant tumors and has become one of the important methods of tumor treatment.

ACTL is a targeted therapy that only attacks tumor cells without harm to other organisms. It has high safety and low side effects. This technology can kill residual lesions that are invisible to the naked eye and cannot be removed by surgery, and can significantly reduce the level of tumor markers. At the same time, it can also reverse the patient's resistance to small molecule targeted drugs. In other words, the treatment of tumors with ACTL technology will not cause damage to the normal cells and tissues of the human body. It is a true "green therapy".